Search

Your search keyword '"Salamé, Ephrem"' showing total 9 results
Start Over Author "Salamé, Ephrem" Journal transplantation
9 results on '"Salamé, Ephrem"'

4. Influence of the ABO Blood Group System on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Author

Mohkam, Kayvan, primary, Abdallah, Raëf, additional, N’kontchou, Gisèle, additional, Ganne, Nathalie, additional, Barbier, Louise, additional, Salamé, Ephrem, additional, Bucur, Petru, additional, Rayar, Michel, additional, Robin, Fabien, additional, Boudjema, Karim, additional, Pietrasz, Daniel, additional, Cherqui, Daniel, additional, Adam, René, additional, Lim, Chetana, additional, Savier, Eric, additional, Scatton, Olivier, additional, Maulat, Charlotte, additional, Suc, Bertrand, additional, Muscari, Fabrice, additional, Laurent, Alexis, additional, Duvoux, Christophe, additional, Heyd, Bruno, additional, Turco, Célia, additional, Doussot, Alexandre, additional, Merle, Philippe, additional, Antonini, Teresa, additional, Lesurtel, Mickaël, additional, Cossé, Cyril, additional, Durand, François, additional, Soubrane, Olivier, additional, Cauchy, François, additional, and Mabrut, Jean-Yves, additional

Published
2021
Full Text
View/download PDF

5. Influence of the ABO Blood Group System on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Author

Mohkam, Kayvan, Abdallah, Raëf, N’kontchou, Gisèle, Ganne, Nathalie, Barbier, Louise, Salamé, Ephrem, Bucur, Petru, Rayar, Michel, Robin, Fabien, Boudjema, Karim, Pietrasz, Daniel, Cherqui, Daniel, Adam, René, Lim, Chetana, Savier, Eric, Scatton, Olivier, Maulat, Charlotte, Suc, Bertrand, Muscari, Fabrice, Laurent, Alexis, Duvoux, Christophe, Heyd, Bruno, Turco, Célia, Doussot, Alexandre, Merle, Philippe, Antonini, Teresa, Lesurtel, Mickaël, Cossé, Cyril, Durand, François, Soubrane, Olivier, Cauchy, François, and Mabrut, Jean-Yves

Published
2022
Full Text
View/download PDF

6. Recipient Selection for Optimal Utilization of Discarded Grafts in Liver Transplantation

Author

Giretti, Giovanni, primary, Barbier, Louise, additional, Bucur, Petru, additional, Marques, Frédéric, additional, Perarnau, Jean-Marc, additional, Ferrandière, Martine, additional, Tellier, Anne-Charlotte, additional, Kerouredan, Vincent, additional, Altieri, Mario, additional, Causse, Xavier, additional, Debette-Gratien, Maryline, additional, Silvain, Christine, additional, and Salamé, Ephrem, additional

Published
2018
Full Text
View/download PDF

7. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus

Author

Saliba, Faouzi, primary, Rostaing, Lionel, additional, Gugenheim, Jean, additional, Durand, François, additional, Radenne, Sylvie, additional, Leroy, Vincent, additional, Neau-Cransac, Martine, additional, Calmus, Yvon, additional, Salamé, Ephrem, additional, Pageaux, Georges-Philippe, additional, Duvoux, Christophe, additional, Taguieva, Naila, additional, Sinnasse-Raymond, Gilles, additional, Sebagh, Mylène, additional, Samuel, Didier, additional, and Marquet, Pierre, additional

Published
2016
Full Text
View/download PDF

8. Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients

Author

Calmus, Yvon, primary, Kamar, Nassim, additional, Gugenheim, Jean, additional, Duvoux, Christophe, additional, Ducerf, Christian, additional, Wolf, Philippe, additional, Samuel, Didier, additional, Vanlemmens, Claire, additional, Neau-Cransac, Martine, additional, Salamé, Ephrem, additional, Chazouillères, Olivier, additional, Declerck, Nicole, additional, Pageaux, Georges-Philippe, additional, Dubel, Laurence, additional, and Rostaing, Lionel, additional

Published
2010
Full Text
View/download PDF

9. Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation.

Author

Maurel P, Prémaud A, Carrier P, Essig M, Barbier L, Rousseau A, Silvain C, Causse X, Debette-Gratien M, Jacques J, Marquet P, Salamé E, and Loustaud-Ratti V

Subjects
Acute Kidney Injury diagnosis, Acute Kidney Injury physiopathology, Adult, Aged, Disease-Free Survival, Female, Glomerular Filtration Rate drug effects, Humans, Immunosuppressive Agents administration & dosage, Kidney physiopathology, Male, Middle Aged, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic physiopathology, Retrospective Studies, Risk Assessment, Risk Factors, Tacrolimus administration & dosage, Time Factors, Acute Kidney Injury chemically induced, Immunosuppressive Agents adverse effects, Kidney drug effects, Liver Transplantation adverse effects, Renal Insufficiency, Chronic chemically induced, Tacrolimus adverse effects
Abstract

Background: Renal failure is predictive of mortality in the early postliver-transplantation period and calcineurin inhibitors toxicity is a main challenge. Our aim is to assess the impact of longitudinal tacrolimus exposure (TLE) and other variables on chronic kidney disease (CKD)-free 1-year-survival., Methods: Retrospective data of consecutive patients transplanted between 2011 and 2016 and treated with tacrolimus were collected. TLE and all relevant pre- and post-liver transplantation (LT) predictive factors of CKD were tested and included in a time-to-event model. CKD was defined by repeated estimated glomerular filtration rate (eGFR) values below 60 mL/min/1.73m2 at least for the last 3 months before M12 post-LT., Results: Data from 180 patients were analyzed. CKD-free survival was 74.5% and was not associated with TLE. Pre-LT acute kidney injury (AKI) and eGFR at 1-month post-LT (eGFRM1) <60 mL/min/1.73m2 were significant predictors of CKD. By distinguishing 2 situations within AKI (ie, with or without hepatorenal syndrome [HRS]), only HRS-AKI remained associated to CKD. HRS-AKI and eGFRM1 <60 mL/min/1.73m2 increased the risk of CKD (hazard ratio, 2.5; 95% confidence interval, 1.2-4.9; hazard ratio, 4.8; 95% confidence interval, 2.6-8.8, respectively)., Conclusions: In our study, TLE, unlike HRS-AKI and eGFRM1, was not predictive of CKD-free survival at 1-year post-LT. Our results once again question the reversibility of HRS-AKI., Competing Interests: M.D.-G. has received funds from Chiesi, Astellas, Roche. P.C. has received funds from Astellas, Roche. V.L.-R. has received funds from Gilead, Abbvie, BMS, MSD. The other authors declare no conflicts of interest., (Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results